We are a clinical stage biopharmaceutical company aspiring to cure solid tumors with our novel TCR like CAR-T cell therapies that enhances the immune system with state of the art technology originated in prof. Hiroshi Shiku laboratory at Mie University.

​We strongly believe that our uniquie TCR like CAR T-cell therapy is a quantum leap toward curing solid tumors, uncovered by modern CAR/TCR-T cell therapies.

Our proprietary TCR like CAR antibody is highly specific against target antigens (MAGEA4 and PRAME) in peptide-MHC complexes.

​Moreover our proprietary signal domain constructs help to activate, maintain and prolong T cell effect in immunosuppressive tumor microenvironment.  

We are proudly delivering this unique technology from prof. Hiroshi Shiku laboratory at Mie University to global medical practice.

​Our Mission:

​Lead to common CAR-T cell therapy for common cancers and common people

Our Values:

Bring value to the current and contribute to the next academic innovation

Meet expectations of medical practitioners for innovation

Always think of patients demanding such innovation

T Cell Nouveau

Org chart

Teams

Offices

T Cell Nouveau

Org chart

Teams

Offices

Related companies